Summit Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Florida, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
601 Brickell Key Dr Ste 1000, Miami, Flo...Phone Number
(650) 382-0001Website
www.smmttx.comRevenue
$33.6 MillionStock Symbol
SMMTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Summit Therapeutics
Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat Duchenne muscular dystrophy. The company is headquartered in Cambridge, UK.Explore more
Summit Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Summit Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Summit Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Summit Therapeutics
Check out if Summit Therapeutics is spiking on competitors!
Summit Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Summit Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Summit Therapeutics has new funding data
Earning: See what the market has to say on Summit Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Summit Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Summit Therapeutics
Compare insights from companies similar to Summit Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Summit Therapeutics
$33.6M
201-500
Public
$1.2B
2003
RM
Rishma MerchantSenior Director and Chief of Staff, Clinical Operations
$827.1M
501-1,000
Public
$2.5B
1998
QN
Quintus NgumahVice President, Clinical Development & Chief Marketing Officer, Cos To The
Company Profile Activity
Activity Insights
Summit Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Summit Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Summit Therapeutics.
Summit Therapeutics financials insights
Gather financial insights about Summit Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$34.2M
2024
Share Placement
$200M
2025
Stock/Share Issuance
$500M
Stock/Share Issuance
$500M
Summit Therapeutics Tech Stack
A closer look at the technologies used by Summit Therapeutics
See more technologies
Most Recent Scoops
Project
Summit Therapeutics has initiated the Phase III HARMONY-GI3 study evaluating ivonescimab plus chemotherapy compared to bevacizumab plus chemotherapy as frontline therapy in patients with unresectable colorectal cancer, supported by Phase II data presented at ESMO 2024 and global Phase II data presented at ASCO 2026.
VoIP
Partnership
Summit Therapeutics has partnered with GSK to evaluate ivonescimab in combination with GSK's B7-H3 antibody-drug conjugate (ADC) across multiple solid tumor settings, including multiple types of lung cancer and colorectal cancer, with first patient enrollment expected later this quarter.
Partnership, Pharmaceuticals
Partnership
Summit Therapeutics has partnered with Revolution Medicines to evaluate ivonescimab in combination with three novel RAS inhibitors across multiple solid tumor settings, including pancreatic, colorectal, and non-small cell lung cancers, with enrollment having begun in Q1 of this year.
Partnership
Project
Summit Therapeutics has announced that the HARMONY-A study in China demonstrated a statistically significant overall survival benefit in a setting consistent with the global HARMONY trial, and that the HARMONY-2 study in China reported an overall survival hazard ratio of 0.78 at 39% data maturity, evaluating ivonescimab monotherapy versus pembrolizumab monotherapy in frontline non-small cell lung cancer with positive PD-L1 expression.
Medical Research, Pharmaceuticals
Project
Clinical Operations
Summit Therapeutics News & Media
Kuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law Firm
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
Cancer treatment is undergoing one of the most significant transformations in modern medical history.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Summit Therapeutics
Sign Up For FreeTo access detailed company insights
Summit Therapeutics is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat Duchenne muscular dystrophy. The company is headquartered in Cambridge, UK.... Read More
